Limited efficacy and unacceptable toxicity of cyclophosphamide for the induction of mixed chimerism and renal allograft tolerance in cynomolgus monkeys.

Transplantation
H SogawaTatsuo Kawai

Abstract

To induce mixed chimerism and renal allograft tolerance in cynomolgus monkeys, cyclophosphamide (CP) and total body irradiation (TBI) were compared as part of a nonmyeloablative conditioning regimen. CP induced dose-dependent neutropenia and lymphopenia, but hematopoietic recovery was more rapid than that observed in the TBI group. Absolute B cell counts after CP were significantly higher (P<0.01) than those in the TBI group. With CP, a total dose of 200 mg/kg with CD154 blockade regularly induced multilineage chimerism. Nevertheless, the recipients failed to achieve long-term survival because of rejection (3 of 5), posttransplantation B cell lymphoma (1 of 5), and toxicities of CP (1 of 5). As previously reported, 3 Gy of TBI with either splenectomy or CD154 blockade induced mixed chimerism and renal allograft tolerance, with significantly less morbidity and mortality than that produced by CP. Thus, TBI is more effective and less toxic than CP as part of a nonmyeloablative regimen for the induction of mixed chimerism and renal allograft tolerance in cynomolgus monkeys.

References

Mar 27, 2001·Journal of Virology·S NikiforowG Miller
Aug 17, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Tatsuo KawaiA Benedict Cosimi
Jun 27, 2006·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Y FudabaM Sykes
Jul 14, 2007·Nature Reviews. Immunology·Adrian E Morelli, Angus W Thomson
Jan 25, 2008·The New England Journal of Medicine·Tatsuo KawaiDavid H Sachs

❮ Previous
Next ❯

Citations

Feb 19, 2010·Folia Histochemica Et Cytobiologica·M Baśkiewicz-MasiukB Machaliński
Oct 4, 2011·Transplant Immunology·Magdalena Baśkiewicz-HałasaBogusław Machaliński
Jan 6, 2010·Microsurgery·Lijun SongHuifang Chen
Sep 21, 2013·Transplant Immunology·M Baśkiewicz-HałasaB Machaliński
Jun 3, 2017·Transplantation·Anita Y ChhabraSuzanne Ildstad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.